7-O-(2-acetamido-3,6-di-O-benzoyl-2-deoxy-4-O-sulfonato-β-D-galactopyranosyl) tert-butyl 6-(7-hydroxy-coumarin-4-acetamido)hexylcarbamate sodium salt | 1255535-26-2

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: 7-O-(2-acetamido-3,6-di-O-benzoyl-2-deoxy-4-O-sulfonato-β-D-galactopyranosyl) tert-butyl 6-(7-hydroxy-coumarin-4-acetamido)hexylcarbamate sodium salt
• CAS: 1255535-26-2
• 化学式: C₄₄H₅₀N₃O₁₆S*Na
• 分子量: 931.947
• InChiKey: YBZPXZJZLWUPMP-SKVPSTOKSA-M

反应信息

• 作为反应物：
  描述：

  7-O-(2-acetamido-3,6-di-O-benzoyl-2-deoxy-4-O-sulfonato-β-D-galactopyranosyl) tert-butyl 6-(7-hydroxy-coumarin-4-acetamido)hexylcarbamate sodium salt 在 甲醇 、 sodium methylate 作用下， 反应 5.0h， 以77%的产率得到7-O-(2-acetamido-2-deoxy-4-O-sulfonato-β-D-galactopyranosyl) tert-butyl 6-(7-hydroxy-coumarin-4-acetamido)hexylcarbamate sodium salt
  参考文献：
  名称：

  Design and synthesis of substrates for newborn screening of Maroteaux–Lamy and Morquio A syndromes

  摘要：

  In continued efforts to develop enzymatic assays for lysosomal storage diseases appropriate for newborn screening laboratories we have synthesized novel and specific enzyme substrates for Maroteaux-Lamy (MPS VI) and Morquio A (MPS IVA) diseases. The sulfated monosaccharide derivatives were found to be converted to product by the respective enzyme in blood from healthy patients but not by blood from patients with the relevant lysosomal storage disease. The latter result shows that the designed substrates are highly selective for the respective enzymes. (c) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.08.080
• 作为产物：
  描述：

  7-O-(2-acetamido-3,6-di-O-benzoyl-2-deoxy-β-D-galactopyranosyl) tert-butyl 6-(7-hydroxy-coumarin-4-acetamido)hexylcarbamate 在 吡啶 、 三氧化硫吡啶 作用下， 以 甲醇 为溶剂， 反应 3.0h， 以56%的产率得到7-O-(2-acetamido-3,6-di-O-benzoyl-2-deoxy-4-O-sulfonato-β-D-galactopyranosyl) tert-butyl 6-(7-hydroxy-coumarin-4-acetamido)hexylcarbamate sodium salt
  参考文献：
  名称：

  Design and synthesis of substrates for newborn screening of Maroteaux–Lamy and Morquio A syndromes

  摘要：

  In continued efforts to develop enzymatic assays for lysosomal storage diseases appropriate for newborn screening laboratories we have synthesized novel and specific enzyme substrates for Maroteaux-Lamy (MPS VI) and Morquio A (MPS IVA) diseases. The sulfated monosaccharide derivatives were found to be converted to product by the respective enzyme in blood from healthy patients but not by blood from patients with the relevant lysosomal storage disease. The latter result shows that the designed substrates are highly selective for the respective enzymes. (c) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.08.080